Phase III ECLIPSE study of Tremfya showed superior long-term efficacy in psoriasis

Results from the Phase III ECLIPSE study, which show superior long-term efficacy of Tremfya (guselkumab), from J&J Janssen Cilag, compared with Cosentyx (secukinumab) in adults with moderate to severe plaque psoriasis. According to data published in The Lancet, the proportion of patients with a PASI 90 response at week 48 was greater in the guselkumab group (451 [84%]) than in the secukinumab group (360 [70%]; p<0·0001). Although non-inferiority (margin of 10 percentage points) was established for the first major secondary endpoint (452 [85%] of patients in the guselkumab group vs 412 [80%] of patients in the secukinumab group achieving a PASI 75 response at both weeks 12 and 48), superiority was not established (p=0·0616). Consequently, formal statistical testing was not done for subsequent major secondary endpoints. Proportions of patients with adverse events, infections, and serious adverse events were similar between the two treatments and, in general, safety findings were consistent with registrational trial observations.

During the trial, patients were randomised to receive 100mg of Tremfya administered by subcutaneous injection at weeks zero and four, followed by every eight-week dosing; or 300mg of Cosentyx administered by two subcutaneous injections of 150mg at weeks zero, one, two, three and four followed by every four-week dosing.

See: "Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase III randomised controlled trial." Kristian Reich et al. The Lancet, August 08, 2019DOI:https://doi.org/10.1016/S0140-6736(19)31773-8